CA2598517A1 - Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease - Google Patents

Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease Download PDF

Info

Publication number
CA2598517A1
CA2598517A1 CA002598517A CA2598517A CA2598517A1 CA 2598517 A1 CA2598517 A1 CA 2598517A1 CA 002598517 A CA002598517 A CA 002598517A CA 2598517 A CA2598517 A CA 2598517A CA 2598517 A1 CA2598517 A1 CA 2598517A1
Authority
CA
Canada
Prior art keywords
compound
effective amount
pharmaceutically effective
pharmaceutically acceptable
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002598517A
Other languages
English (en)
French (fr)
Inventor
John Ernest Doe
Nicholas Crispinian Sturgess
Kim Zachary Travis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2598517A1 publication Critical patent/CA2598517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002598517A 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease Abandoned CA2598517A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
GB0504103.3 2005-02-28
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE

Publications (1)

Publication Number Publication Date
CA2598517A1 true CA2598517A1 (en) 2006-08-31

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002598517A Abandoned CA2598517A1 (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease

Country Status (17)

Country Link
US (1) US20090326072A1 (https=)
EP (1) EP1853241B1 (https=)
JP (1) JP2008531665A (https=)
CN (1) CN101163466B (https=)
AT (1) ATE524171T1 (https=)
AU (1) AU2006217650B2 (https=)
BR (1) BRPI0609177A2 (https=)
CA (1) CA2598517A1 (https=)
DK (1) DK1853241T3 (https=)
ES (1) ES2374761T3 (https=)
GB (1) GB0504103D0 (https=)
IL (1) IL185410A0 (https=)
MX (1) MX2007010480A (https=)
PT (1) PT1853241E (https=)
RU (1) RU2420272C2 (https=)
WO (1) WO2006090177A1 (https=)
ZA (1) ZA200707486B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
RS54632B1 (sr) 2011-06-23 2016-08-31 Swedish Orphan Biovitrum International Ab Tečna farmaceutska kompozicija koja sadrži nitizinon
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
TW202543611A (zh) * 2024-03-27 2025-11-16 美商費斯製藥有限公司 Ｈｐｄ抑制劑組成物及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
JP3130935B2 (ja) * 1991-06-24 2001-01-31 ゼネカ リミテッド 医薬組成物
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
WO2005007096A2 (en) * 2003-07-11 2005-01-27 Merck & Co., Inc. Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
NZ574153A (en) * 2006-08-18 2011-12-22 Syngenta Ltd Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders

Also Published As

Publication number Publication date
CN101163466A (zh) 2008-04-16
PT1853241E (pt) 2012-01-11
DK1853241T3 (da) 2012-01-16
RU2420272C2 (ru) 2011-06-10
GB0504103D0 (en) 2005-04-06
HK1110211A1 (en) 2008-07-11
AU2006217650A1 (en) 2006-08-31
AU2006217650B2 (en) 2011-06-09
ES2374761T3 (es) 2012-02-21
ZA200707486B (en) 2009-02-25
IL185410A0 (en) 2008-08-07
MX2007010480A (es) 2008-02-07
RU2007131934A (ru) 2009-02-27
JP2008531665A (ja) 2008-08-14
US20090326072A1 (en) 2009-12-31
ATE524171T1 (de) 2011-09-15
EP1853241A1 (en) 2007-11-14
WO2006090177A1 (en) 2006-08-31
BRPI0609177A2 (pt) 2010-02-23
EP1853241B1 (en) 2011-09-14
CN101163466B (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
JP2022037132A (ja) 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用
US20060229347A1 (en) Treatment of eczemas
EP1853241B1 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
EP3444249A1 (en) Sodium channel blockers, preparation method thereof and use thereof
WO2023122320A1 (en) Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists
CN112274524A (zh) 人参二醇皂苷Rb组分在制备防治代谢紊乱相关疾病药物中的应用
JP2022544299A (ja) リモノイド化合物およびチアゾリジンジオン化合物を含有する組合せ製品
KR20080033456A (ko) 염증성 피부 상태의 치료를 위한 식물수 조성물
JP2018177739A (ja) Ｔｒｐａ１活性化剤
JP2016534055A (ja) オイゲノールを有効成分として含有するアトピー性皮膚炎の予防又は治療用組成物
EP2994461B1 (en) Methods of treating skin conditions using cyclolignan compounds
WO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
CA2659424A1 (en) Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
HK1110211B (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione in the treatment of parkinson's disease
Li et al. Discovery and development of tricyclic matrinic derivatives as anti-diabetic candidates by AMPKα activation
KR102105533B1 (ko) 아마이드 유도체 화합물
HK1142836A (en) Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
KR101906896B1 (ko) 티몰 및 미르센을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물
KR20090096640A (ko) 당뇨병성 뉴로퍼시 치료제
KR102251917B1 (ko) N-사이아노설폰아마이드를 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학적 조성물
Williams et al. Xanthine Oxidase-Induced Vascular Dysfunction in Inhalation Toxicology: 163
KR20200105469A (ko) 푸니칼라진을 포함하는 소양증 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131114